

Pathologic Complete Response after Neoadjuvant Chem Cancer Recurrence and Survival: A Comprehensive Met

Clinical Cancer Research

26, 2838-2848

DOI: [10.1158/1078-0432.ccr-19-3492](https://doi.org/10.1158/1078-0432.ccr-19-3492)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020, 80, 1811-1830.	4.9	23
2	Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 566511.	1.3	202
3	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
4	A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 861-872.	1.1	8
5	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	1.7	10
7	Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP). <i>Breast Cancer Research and Treatment</i> , 2020, 184, 481-489.	1.1	2
8	Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 97-105.	1.1	36
9	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
10	<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2423-2433.	2.0	82
11	Trastuzumab: Weighing the Benefits and the Risks. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1181-1182.	3.0	2
12	<p>The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2491-2499.	0.9	3
13	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 157-165.	1.1	12
14	Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Sonography Using Siamese Convolutional Neural Networks. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021, 25, 797-805.	3.9	35
15	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. <i>Modern Pathology</i> , 2021, 34, 875-882.	2.9	18
16	Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 527-534.	1.1	18
17	Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery. <i>Surgical Oncology</i> , 2021, 36, 91-98.	0.8	10
18	Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival. <i>Breast Cancer</i> , 2021, 28, 307-320.	1.3	5
19	The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. <i>BMC Cancer</i> , 2021, 21, 90.	1.1	11

#	ARTICLE	IF	CITATIONS
20	Recent advances in neoadjuvant therapy for breast cancer. Faculty Reviews, 2021, 10, 2.	1.7	8
21	Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features. JCO Clinical Cancer Informatics, 2021, 5, 66-80.	1.0	25
22	Update on systemic treatment in early triple negative breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098674.	1.4	19
23	Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy. Journal of Cancer, 2021, 12, 5365-5374.	1.2	6
24	A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy. Frontiers in Oncology, 2020, 10, 592556.	1.3	5
25	Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data. Ecancermedalscience, 2021, 15, 1178.	0.6	5
26	Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. Breast Cancer Research and Treatment, 2021, 187, 167-176.	1.1	1
27	Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research, 2021, 27, 2148-2158.	3.2	12
29	Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital. Ecancermedalscience, 2021, 15, 1185.	0.6	3
30	Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy±Trastuzumab in Locally Advanced Breast Cancer. Journal of Oncology, 2021, 2021, 1-10.	0.6	2
31	Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. Breast Cancer Research and Treatment, 2021, 186, 753-760.	1.1	3
32	Clinical application of circulating tumor DNA in breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1431-1442.	1.2	5
33	Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India. Ecancermedalscience, 2021, 15, 1207.	0.6	3
34	Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 199-211.	1.0	15
35	Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment. BMC Surgery, 2021, 21, 160.	0.6	5
36	Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. Npj Breast Cancer, 2021, 7, 32.	2.3	23
37	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer, 2021, 28, 1023-1037.	1.3	5
38	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opinion on Emerging Drugs, 2021, 26, 131-147.	1.0	5

#	ARTICLE	IF	CITATIONS
39	Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 9922.	1.6	10
40	Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. <i>Breast Cancer Research</i> , 2021, 23, 61.	2.2	12
41	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424.	1.6	33
42	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1485-1505.	0.8	395
43	Highlights of the 17th St. Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. <i>Ecancelmedicalscience</i> , 2021, 15, 1236.	0.6	8
44	Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival. <i>Anticancer Research</i> , 2021, 41, 2697-2709.	0.5	13
45	Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 93-101.	1.1	1
46	Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 686591.	1.3	0
48	Quantitative Assessment of the Echogenicity of a Breast Tumor Predicts the Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 3546.	1.7	1
49	Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 592393.	1.3	1
50	Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2021, 11, 14662.	1.6	49
51	Is there a correlation between miR-301a expression and neoadjuvant chemotherapy efficacy in breast cancer tissue?. <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100947.	0.7	2
52	Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	3
54	De-escalating Local Treatment for Women with Breast Cancer. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	0
55	Physicians's Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer. <i>Breast Care</i> , 2022, 17, 180-187.	0.8	0
56	Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers. <i>Frontiers in Oncology</i> , 2021, 11, 622621.	1.3	19
57	The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8290.	1.8	29
58	First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1913-1919.	0.5	3

#	ARTICLE	IF	CITATIONS
59	Millerâ€™Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 735670.	1.3	4
60	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. <i>Nature Reviews Urology</i> , 2021, , .	1.9	6
61	Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 737-745.	1.1	3
62	Expression of Senescence and Apoptosis Biomarkers in Synchronous Bilateral Breast Cancer: A Case Report. <i>Current Oncology</i> , 2021, 28, 3836-3845.	0.9	2
63	The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. <i>Breast</i> , 2021, 59, 58-66.	0.9	4
64	Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer â€™ A retrospective cohort study. <i>Breast</i> , 2021, 59, 67-75.	0.9	22
65	Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection. <i>Cancers</i> , 2021, 13, 296.	1.7	4
66	The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 78.	1.1	23
67	Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 379-389.	1.1	19
68	The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism. <i>British Journal of Cancer</i> , 2021, 124, 1187-1198.	2.9	21
69	Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 12.	0.1	0
70	Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy. <i>Annals of Translational Medicine</i> , 2020, 8, 1694-1694.	0.7	2
71	Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. <i>Advances in Therapy</i> , 2021, 38, 5752-5762.	1.3	0
72	The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 60-66.	0.5	4
73	MicroRNA Expression Profiles and Breast Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10812.	1.8	30
74	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 5260.	1.7	11
75	Construction and Validation of a Serum Albumin-to-Alkaline Phosphatase Ratio-Based Nomogram for Predicting Pathological Complete Response in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 681905.	1.3	6
76	Personalization of Treatment is the Way Forward in Care and Trials. <i>Clinical Cancer Research</i> , 2020, 26, 2771-2773.	3.2	2

#	ARTICLE	IF	CITATIONS
77	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 731148.	1.3	5
78	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 5442.	1.7	1
79	The predictive value of DKI in breast cancer: Does tumour subtype affect pathological response evaluations?. <i>Magnetic Resonance Imaging</i> , 2022, 85, 28-34.	1.0	12
80	Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 1526-1527.	0.7	7
81	Pathologic response as predictor of recurrence, metastasis, and survival in breast cancer patients receiving neoadjuvant chemotherapy and total mastectomy. <i>American Journal of Cancer Research</i> , 2020, 10, 3415-3427.	1.4	8
82	Prediction of neoadjuvant chemotherapy response in breast cancer. <i>EXCLI Journal</i> , 2021, 20, 625-627.	0.5	0
83	Clinical endpoints in oncology - a primer. <i>American Journal of Cancer Research</i> , 2021, 11, 1121-1131.	1.4	2
84	Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study. <i>Radiology</i> , 2022, 302, 516-524.	3.6	10
85	Adjuvant abemaciclib for high-risk breast cancer: the story continues. <i>Annals of Oncology</i> , 2021, 32, 1457-1459.	0.6	2
86	Invited commentary on "Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancer: Real-world data from a single center in India". <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100487.	0.7	0
87	Correlation of pathological complete response with outcomes in locally advanced breast cancer treated with neoadjuvant chemotherapy: An ambispective study. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 611.	0.1	5
89	De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. <i>The Journal of Breast Health</i> , 2022, 18, 6-12.	0.4	4
90	Management of triple-negative breast cancer in the era of novel therapies: A narrative review. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 668.	0.1	4
91	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. <i>Oncologist</i> , 2022, 27, 30-39.	1.9	10
92	Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 523.	1.7	4
93	Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancers</i> , 2022, 14, 534.	1.7	8
94	Is adjuvant chemotherapy necessary in older patients with breast cancer?. <i>Breast Cancer</i> , 2022, , 1.	1.3	2
95	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132

#	ARTICLE	IF	CITATIONS
96	Terapia personalizada en c�ncer de mama precoz. Implicancias pr�cticas. Revista M�dica Cl�nica Las Condes, 2022, 33, 17-24.	0.2	0
97	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
98	Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon. <i>International Journal of Breast Cancer</i> , 2022, 2022, 1-6.	0.6	3
99	Second-Harmonic Generation Imaging Reveals Changes in Breast Tumor Collagen Induced by Neoadjuvant Chemotherapy. <i>Cancers</i> , 2022, 14, 857.	1.7	1
100	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	1.3	7
101	Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis. <i>BJS Open</i> , 2022, 6, .	0.7	21
102	Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer – A Systematic Review. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342210866.	0.6	3
103	Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 553-560.	0.5	1
104	Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. <i>Journal of Chemotherapy</i> , 2023, 35, 29-38.	0.7	2
105	Effect of Early-Stage Human Breast Carcinoma on Monocyte Programming. <i>Frontiers in Oncology</i> , 2021, 11, 800235.	1.3	17
106	A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 784839.	1.3	0
107	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	2.3	9
108	Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas. <i>Frontiers in Oncology</i> , 2022, 12, 850401.	1.3	5
109	Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. <i>Academic Radiology</i> , 2022, 29, 1469-1479.	1.3	3
110	Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy. <i>Uspehi Molekularnoj Onkologii</i> , 2022, 9, 33-41.	0.1	1
111	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. <i>Npj Breast Cancer</i> , 2022, 8, 42.	2.3	9
112	Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 63-70.	1.0	1
113	Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100310.	0.6	1

#	ARTICLE	IF	CITATIONS
114	Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021). Chinese Medical Journal, 2022, 135, 697-706.	0.9	5
115	Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy. Journal of Clinical Medicine, 2022, 11, 1607.	1.0	4
116	Dual-Branch Convolutional Neural Network Based on Ultrasound Imaging in the Early Prediction of Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Breast Cancer. Frontiers in Oncology, 2022, 12, 812463.	1.3	6
117	Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-11.	0.7	7
119	Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer. Meditsinskiy Sovet, 2021, , 68-74.	0.1	0
121	Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials. Npj Breast Cancer, 2021, 7, 157.	2.3	10
122	Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer. Cancer Management and Research, 2021, Volume 13, 9235-9246.	0.9	3
123	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori, 2022, 108, 196-203.	0.6	6
124	Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience. Journal of the Egyptian National Cancer Institute, 2021, 33, 39.	0.6	5
125	Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study. Gland Surgery, 2021, 10, 3389-3402.	0.5	3
126	Towards Patient-Specific Optimization of Neoadjuvant Treatment Protocols for Breast Cancer Based on Image-Guided Fluid Dynamics. IEEE Transactions on Biomedical Engineering, 2022, 69, 3334-3344.	2.5	10
127	Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. Frontiers in Oncology, 2022, 12, 860475.	1.3	5
130	Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer.. American Journal of Translational Research (discontinued), 2022, 14, 460-467.	0.0	0
131	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. Journal of Breast Cancer, 2022, 25, 94.	0.8	4
132	Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precision Oncology, 2022, 6, e2100463.	1.5	10
133	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. Npj Breast Cancer, 2022, 8, 60.	2.3	11
134	Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 5324.	1.8	6
135	Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Annals of Oncology, 2022, 33, 814-823.	0.6	11

#	ARTICLE	IF	CITATIONS
136	Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer. <i>Pathology Research and Practice</i> , 2022, 234, 153915.	1.0	0
137	Iron Single-Atom nanocatalysts in response to tumor microenvironment for highly efficient Chemo-chemodynamic therapy. <i>Journal of Industrial and Engineering Chemistry</i> , 2022, 112, 210-217.	2.9	6
138	Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 486-494.	1.8	3
139	Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy. <i>JCO Global Oncology</i> , 2022, 8, e2200016.	0.8	5
141	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	7.7	92
142	Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology. <i>Biophysics Reviews</i> , 2022, 3, .	1.0	21
143	Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer. <i>Journal of Surgical Research</i> , 2022, 278, 223-232.	0.8	3
144	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 47-59.	1.8	8
145	Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
146	Editorial for "4D Machine Learning Radiomics for the Prediction of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast-Enhanced MRI". <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 111-112.	1.9	0
147	Efficacy and Safety of Albumin-bound Paclitaxel Versus Solvent-based Paclitaxel in Breast Cancer: A Meta-analysis. , 2022, 2, .		0
148	A Novel Combined Nomogram Model for Predicting the Pathological Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Carcinoma of No Specific Type: Real-World Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
149	Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers. <i>Future Oncology</i> , 2022, 18, 2817-2825.	1.1	2
150	Whole lesion histogram analysis of apparent diffusion coefficient predicts therapy response in locally advanced rectal cancer. <i>World Journal of Gastroenterology</i> , 2022, 28, 2609-2624.	1.4	1
151	The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 723-734.	2.3	19
152	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
153	Clinicopathological factors predictive of pathological response and impact on disease-free survival in breast cancer: Analysis from a tertiary cancer centre in South India. <i>Journal of Radiation and Cancer Research</i> , 2022, 13, 54.	0.0	0
154	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956.	0.8	46

#	ARTICLE	IF	CITATIONS
155	Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3268-3276.	3.2	24
156	Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
157	Is There a Relation Between Pretreatment CONUT Score and Neoadjuvant Chemotherapy Response in Breast Cancer Patients?. <i>Medical Journal of Bakirkoy</i> , 2022, 18, 146-150.	0.0	0
158	Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics. <i>European Radiology</i> , 2022, 32, 6575-6587.	2.3	7
159	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4995-5003.	3.2	6
160	Predictive Role of <i>CD36</i> Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1720-1727.	3.0	10
161	The landscape of systemic therapy for early stage triple-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1291-1303.	0.9	4
162	Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer. <i>Irish Journal of Medical Science</i> , 0, , .	0.8	1
163	Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study. <i>Anticancer Research</i> , 2022, 42, 3735-3742.	0.5	2
164	Intermediate results of the prospective randomized controlled trial VOG-01: "Evaluation of the efficacy of neoadjuvant combination hormone therapy in premenopausal patients with ER+ HER2-breast cancer". <i>Voprosy Onkologii</i> , 2022, 68, 354-361.	0.1	0
166	Locoregional Management of Breast Cancer Following Neoadjuvant Chemotherapy. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0
167	Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2022, 276, 905-912.	2.1	16
168	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	31
169	Study of response of axillary lymph nodal metastases toneoadjuvant chemotherapy in carcinoma breast. <i>International Journal of Health Sciences</i> , 0, , 8976-8987.	0.0	0
170	Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100384.	0.6	8
171	Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. <i>Cancer Management and Research</i> , 0, Volume 14, 2493-2506.	0.9	3
172	MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2022, 82, 3394-3404.	0.4	18
173	Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12

#	ARTICLE	IF	CITATIONS
174	Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer. <i>Current Oncology</i> , 2022, 29, 5810-5822.	0.9	4
176	Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-7.	0.4	2
177	Diagnostic precision of breast MRI in prediction of pathological complete response: Is it influenced by the presence of metallic markers?. <i>European Journal of Radiology</i> , 2022, 154, 110453.	1.2	0
178	Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study. <i>EClinicalMedicine</i> , 2022, 52, 101562.	3.2	15
179	Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients With MRI-Radiomics: A Systematic Review and Meta-analysis. <i>Current Problems in Cancer</i> , 2022, 46, 100883.	1.0	14
180	Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102459.	3.4	9
182	Multifunctional drug delivery nanoparticles based on MIL-100 (Fe) for photoacoustic imaging-guided synergistic chemodynamic/chemo/photothermal breast cancer therapy. <i>Materials and Design</i> , 2022, 223, 111132.	3.3	16
183	Preoperative Radiation. , 2022, , 303-310.		0
184	Stromal Tumor Infiltrating Lymphocytes (sTIL) as an Independent Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer in Indonesia: A Hospital-based Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2763-2769.	0.5	0
185	An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2022, 14, 4170.	1.7	3
186	An Alternatively Spliced p62 Isoform Confers Resistance to Chemotherapy in Breast Cancer. <i>Cancer Research</i> , 2022, 82, 4001-4015.	0.4	7
187	The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy. <i>International Journal of Breast Cancer</i> , 2022, 2022, 1-10.	0.6	1
188	Time to Optimize Deescalation Strategies in Triple-Negative Breast Cancer?. <i>Clinical Cancer Research</i> , 2022, 28, 4840-4842.	3.2	1
189	The Impact of Chemotherapy Prescription on Long-Term Survival Outcomes in Early-Stage Invasive Lobular Carcinoma – A Systematic Review and Meta-Analysis. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	3
190	Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy. <i>Cancer Medicine</i> , 2023, 12, 2906-2917.	1.3	3
191	Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. <i>Cancers</i> , 2022, 14, 4436.	1.7	7
192	Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. <i>Cancers</i> , 2022, 14, 4531.	1.7	3
193	Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis. <i>Diagnostics</i> , 2022, 12, 2294.	1.3	0

#	ARTICLE	IF	CITATIONS
194	Canadian Perspectives on Using Pharmacodynamic Markers for Biosimilar Development and Authorization. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 27-29.	2.3	1
195	De-Escalating the Management of In Situ and Invasive Breast Cancer. <i>Cancers</i> , 2022, 14, 4545.	1.7	5
196	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	15
197	Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1031-1031.	0.7	2
198	Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
199	Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. <i>Clinical Breast Cancer</i> , 2022, 22, 781-791.	1.1	1
200	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
201	Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. <i>Cancer</i> , 2022, 128, 3796-3803.	2.0	5
202	Mammographic and Ultrasonographic Imaging Analysis for Neoadjuvant Chemotherapy Evaluation: Volume Reduction Indexes That Correlate With Pathological Complete Response. <i>Cureus</i> , 2022, , .	0.2	0
203	Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
204	Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis. <i>Breast</i> , 2022, 66, 97-109.	0.9	11
205	Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+ Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1779-1789.	1.8	2
206	Funding of Clinical Trials Through Non-Profit and Third-Party Organizations: A Case Study of the CREATE-X Trial in Japan. , 2022, , 439-450.		0
207	Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. <i>Cancers</i> , 2022, 14, 5051.	1.7	8
208	Patient-derived primary breast cancer cells and their potential for predicting sensitivity to chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
209	Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 343-350.	1.0	0
210	A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
212	Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , 2023, 55, 592-602.	1.3	3

#	ARTICLE	IF	CITATIONS
213	Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12625.	1.8	12
214	HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
215	The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis. <i>European Journal of Radiology</i> , 2022, 157, 110561.	1.2	9
216	A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. <i>European Radiology</i> , 2023, 33, 2171-2184.	2.3	3
218	Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , .	1.1	0
219	Phytochemical Targeting of Mitochondria for Breast Cancer Chemoprevention, Therapy, and Sensitization. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14152.	1.8	5
220	The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 333-341.	1.1	1
221	Establishment of a Prognostic Model and Nomogram in Breast Cancer Based on LASSO. <i>Advances in Clinical Medicine</i> , 2022, 12, 10290-10298.	0.0	0
222	Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103880.	2.0	0
223	Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 103-115.	0.9	1
224	Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211396.	1.4	4
225	Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015). <i>Chinese Medical Journal</i> , 2022, 135, 2311-2318.	0.9	0
226	Deep Learning Prediction of Pathologic Complete Response in Breast Cancer Using MRI and Other Clinical Data: A Systematic Review. <i>Tomography</i> , 2022, 8, 2784-2795.	0.8	12
227	Using the<i>HER2/CEP17</i>FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. <i>Oncologist</i> , 2023, 28, 123-130.	1.9	2
228	Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2022, , .	1.3	1
229	ASO Author Reflections: Development of Natural Language Processing-Based Machine-Learning Algorithms to Identify Pathologic Complete Response from Surgical Pathology Reports. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
230	Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
231	Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
232	A New Method of Identifying Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Patients Using a Population-Based Electronic Medical Record System. <i>Annals of Surgical Oncology</i> , 2023, 30, 2095-2103.	0.7	3
233	Why Should We Avoid Excisional Biopsy of Breast Lump? ASOMA Guide for Managing a Discrete Breast Lump. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
234	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. <i>IScience</i> , 2023, 26, 105799.	1.9	12
235	Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
236	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
237	Cpt1c Downregulation Causes Plasma Membrane Remodelling and Anthracycline Resistance in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 946.	1.8	0
238	Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1870.	1.8	1
239	Breast-conserving therapy leads to better survival outcomes compared to mastectomy in patients with early breast cancer: evidences from the recent literature. <i>Minerva Surgery</i> , 2023, 78, .	0.1	4
240	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. <i>DNA and Cell Biology</i> , 2023, 42, 73-81.	0.9	2
241	Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. <i>BMC Medicine</i> , 2022, 20, .	2.3	10
242	Molecular hallmarks of breast multiparametric magnetic resonance imaging during neoadjuvant chemotherapy. <i>Radiologia Medica</i> , 0, , .	4.7	0
243	Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 409-417.	0.6	5
244	Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. <i>Diagnostics</i> , 2023, 13, 372.	1.3	4
245	Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
246	Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211503.	0.8	1
247	End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTO. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
248	A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 217-229.	1.1	1
249	The prognostic differences and the effect of postmastectomy radiotherapy between post-chemotherapy $T1N1$ and de novo $T1N1$ breast cancer. <i>Cancer Medicine</i> , 2023, 12, 8112-8121.	1.3	2

#	ARTICLE	IF	CITATIONS
250	Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 349-359.	1.1	4
251	De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 3796-3804.	0.8	7
252	Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2023, 11, 200-200.	0.7	4
253	A Review of Endocrine Therapy in Early-stage Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	0
254	Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2023, 23, 339-349.	1.1	1
255	ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	9
256	Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
257	The use of neoadjuvant systemic therapies in breast cancer in Australia and New Zealand: Breast Surgeons of Australia and New Zealand quality audit. <i>ANZ Journal of Surgery</i> , 2023, 93, 889-895.	0.3	0
258	Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. <i>Oncology and Therapy</i> , 0, , .	1.0	0
259	Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
260	Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	1.0	3
261	Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers. <i>Future Oncology</i> , 2023, 19, 229-244.	1.1	0
263	Impact of Chemotherapy Regimens on Body Composition of Breast Cancer Women: A Multicenter Study across Four Brazilian Regions. <i>Nutrients</i> , 2023, 15, 1689.	1.7	0
265	Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. <i>Radiotherapy and Oncology</i> , 2023, 184, 109668.	0.3	3
266	Impact of Pathologic Complete Response on the Prognosis of Triple-Negative Breast Cancer Patients: A Cohort Study. <i>Cureus</i> , 2023, , .	0.2	0
267	Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer. <i>Cureus</i> , 2023, , .	0.2	1
268	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. <i>Investigational New Drugs</i> , 0, , .	1.2	0
269	Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 313-322.	1.0	0

#	ARTICLE	IF	CITATIONS
270	Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors. <i>Cancer Control</i> , 2023, 30, .	0.7	1
271	Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response. <i>Bioengineering</i> , 2023, 10, 485.	1.6	1
272	Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-HER2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2998-3008.	0.8	14
283	Obesity and Cancer: Two Sides of the Same Coin. <i>Obesity Surgery</i> , 2023, 33, 2253-2254.	1.1	0
317	Wavelet transform and deep learning for breast cancer neoadjuvant chemotherapy efficacy prediction. , 2023, , .		0
343	miRNAs as biomarkers breast cancer and their influence on tumor epigenetics. , 2024, , 173-205.		0
356	Imaging-proteomics co-profiling reveals biologic pathways underlying prognostic MRI features. , 2023, , .		0
396	Multi-Modal Cross Attention Network for Predicting Pathological Complete Response in Breast Cancer MRI. , 2023, , .		0